Asia Pacific Biocomposites Industry Poised for Remarkable Growth, Projected to Reach US$ 27,817.3 Million by 2032

The Asia-Pacific biocomposite industry is poised for substantial growth, projected to reach a value of US $27,817.3 million by 2032. This surge is attributed to the escalating industrialization and expansion of the construction industry, coupled with a rising demand for consumer goods and products in the transportation and automotive sectors on a global scale. According to Future Market Insights (FMI), the market is estimated to be valued at US$ 8,603.5 million in 2022, with a projected compound annual growth rate (CAGR) of 13.4% throughout the forecast period, reflecting the robust momentum in the region’s biocomposite industry.

The Asia Pacific region is witnessing a transformative shift towards sustainable and eco-friendly solutions, with the bio-composites market emerging as a key player in this landscape. Bio-composites, made from natural fibers and bio-based resins, are gaining traction as a viable alternative to traditional materials in various industries. This market’s growth is fueled by increasing environmental awareness, stringent regulations, and the pursuit of sustainable practices.

Request Your Sample Report Now! https://www.futuremarketinsights.com/reports/sample/rep-ap-77

Market Dynamics:

  1. Environmental Awareness and Sustainability Drive: The Asia Pacific bio-composites market is being propelled by a growing awareness of environmental issues and the need for sustainable practices. Bio-composites offer a greener alternative to conventional materials, reducing carbon footprints and promoting a circular economy.
  2. Regulatory Initiatives: Stringent regulations and policies promoting sustainable practices and reducing reliance on non-renewable resources are driving the adoption of bio-composites in the region. Governments are incentivizing industries to shift towards eco-friendly alternatives, fostering the growth of the market.
  3. Versatility Across Industries: Bio-composites find applications in a myriad of industries, including automotive, construction, packaging, and consumer goods. The versatility of bio-composites in terms of strength, durability, and lightweight properties makes them a preferred choice for manufacturers seeking sustainable solutions.
  4. Advancements in Technology: Ongoing research and development efforts are enhancing the properties of bio-composites, making them increasingly competitive with traditional materials. Innovations in processing technologies and the development of new bio-based resins are expanding the market potential.

Key Companies Profiled

  • Flexform Technologies,
  • Technaro GmbH,
  • Procotex
  • S.A. Corporation
  • NV
  • Greengran B.V.
  • Stemergy,
  • Bast Fibers,
  • LLC
  • Crailar

Get in Touch with Our Sales Team to Secure Your Copy of the Report Now! https://www.futuremarketinsights.com/checkout/77

Key Segments Profiled in the Bio Composites Industry Report

By Product Type

  • Hybrid Bio Composites
  • Green Bio Composites

By Fiber Type

  • Wood Fiber
  • Non Wood Fiber

By Polymer Type

  • Synthetic Polymer
  • Natural Polymer

By End Use Industries

  • Construction & Building
  • Transportation
  • Consumer Goods
  • Others (Electrical & Electronics, etc.)

By Country

  • China
  • Japan
  • India
  • South Korea
  • ASEAN
  • Oceania

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:       

Nandini Singh Sawlani  

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Frontotemporal Dementia Management Industry is expected to experience a 6% CAGR growth according to FMI’s projections until 2033

The global frontotemporal dementia management industry demand is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.

Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management. These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia.

To Remain Ahead of Your Competitors, Request For A Sample! https://www.futuremarketinsights.com/reports/sample/rep-gb-16489

According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause for Frontotemporal dementia is still unknown it majorly affects the individual between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.

North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives, increase in the number of research partnerships, presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.

Key Takeaways from the Market Study:

  • From 2018 to 2022, the Frontotemporal Dementia Management market grew at a CAGR of 4%.
  • The global Frontotemporal Dementia Management market is expected to grow with a 6% CAGR during 2023 to 2033.
  • As of 2033, the Frontotemporal Dementia Management Market is expected to reach US$ 17.91 Million
  • According to the FMI analysis, hospitals account for the largest market share.
  • North America is expected to possess 25% market share for the Frontotemporal Dementia Management market.
  • The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Frontotemporal Dementia Management.” says an FMI analyst

Connect With Our Analyst To Address Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16489

Market Competition:

Key players in the Frontotemporal Dementia Management market are

  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Mylan N.V.
  • Merck & Company, Inc.
  • AstraZeneca plc.
  • Allergen plc

Recent Development:

  • In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
  • Alzheimer’s Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.

Discover the Future of Marketing: Get Your Hands on Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16489

Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey:

Drug Class Type:

  • Antidepressants
    • Fluoxetine
    • Fluvoxamine
    • Sertraline
    • Paroxetine
    • Citalopram
    • Bupropion
    • Mirtazapine
  • Antipsychotics
    • Olanzapine
    • Quetiapine
    • Ziprasidone
    • Aripiprazole
    • Risperidone
    • Paliperidone

End-Users:

  • Hospitals
  • Specialty clinics
  • Others

Distribution Channel:

  • Hospital Pharmacy
  • Drug store
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Tuberculous Meningitis Treatment Industry is poised to reach an astonishing US$ 300 Billion by 2033, as analyzed by FMI

A recently published study by FMI expects the global tuberculous meningitis treatment industry to augment at a 7.2% CAGR from 2023 to 2033. The global tuberculous meningitis treatment market garnered a market value of US$ 150 Billion in 2023, by the end of the said assessment period, a valuation of US$ 300 billion is expected for the market. Rapid advancements in healthcare and diagnostic technologies that allow for precise diagnosis in a short period of time are favourably affecting demand in the worldwide tuberculous meningitis treatment market.

A rise in research and development efforts aimed at generating unique and accurate diagnosis solutions is likely to drive demand dynamics in the worldwide tuberculous meningitis treatment market from 2023 to 2033. However, a scarcity of qualified professionals capable of operating or handling new technological solutions and testing equipment may stymie the worldwide market’s expansion in the approaching years. The emphasis on vaccination is growing, particularly in emerging nations, as public knowledge grows and wealth to spend on healthcare rises. In both developing and developed countries, there is an optimistic movement toward the reimbursement situation.

Get your Sample Report with Latest Market Information! https://www.futuremarketinsights.com/reports/sample/rep-gb-16477

Tuberculous meningitis incidence rates in poor nations such as Africa and India are 10 times greater than in industrialised countries because access to disease prevention methods is still limited. Every year, 8000 cases of tuberculous meningitis are reported, with a total of 2000 deaths, indicating that this illness has a significant morbidity and fatality rate. North America continues to be the most important market, followed by Europe. The Asia-Pacific market is expanding, owing to increased government-based immunisation campaigns.

Key Takeaways from the Market Study:

  • FMI projects the global tuberculous meningitis treatment market to expand at a 7.2% value CAGR by 2033
  • The global tuberculous meningitis treatment market is estimated at a market value of US$ 150 Billion
  • The global tuberculous meningitis treatment market is expected to garner a market value of US$ 300 Billion
  • Asia Pacific is forecast to be the most lucrative for tuberculous meningitis treatment market growth
  • North America is expected to grow at a CAGR of 6.9% in the assessment period 2023-2033.
  • Europe is expected to grow at a CAGR of 6.7% in the assessment period 2023-2033.
  • The adjunctive corticosteroid therapy segment is expected to hold the largest market share for tuberculous meningitis treatment in the forecast period 2023-2033.

“Tuberculous meningitis treatment market development may also be linked to reasons such as increased cross-country travel and an increase in the number of traffic accidents. A lot has been occurring in the vaccine R&D area as well, according to future clinical trial results.”Says an analyst at FMI

Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-16477

Market Competition:

Key players in the tuberculous meningitis treatment market are

  • Pfizer Inc.
  • GSK Inc.
  • Sanofi S.A
  • Novartis A.G
  • Merck & Co.
  • AstraZeneca Plc.
  • Biomed Pvt. Ltd
  • K.T.Z Company Limited
  • Sumitomo Group
  • Baxter International

Recent Developments:

  • In January 2023, Baxter International Inc., a leading global medtech firm announced a comprehensive strategic plan to increase operational efficiencies, boost long-term performance, accelerate innovation, and create extra value for all stakeholders. These changes include the company’s plan to spin off its Renal Care and Acute Therapies global business units (GBUs) into a separate, publicly traded company; a simplified commercial and manufacturing footprint to improve underlying business performance; and additional portfolio actions to improve Baxter’s capital structure, including a review of strategic alternatives for the BioPharma Solutions (BPS) business.
  • In December 2022, Pfizer Inc. said that the FDA has accepted for consideration a Biologics License Application (BLA) for its experimental pentavalent meningococcal vaccination candidate (MenABCWY). MenABCWY was filed by Pfizer for the prevention of meningococcal illness caused by the most frequent serogroups in people aged 10 to 25.

Personalized Solutions for Every Industry: Discover More in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16477

Key Segments Profiled in the Tuberculous Meningitis Treatment Market Survey:

By Treatment:

  • Antibiotic Therapy
  • Adjunctive Corticosteroid Therapy
  • Neurosurgical Management

By End User:

  • Hospitals
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Idiopathic Pulmonary Fibrosis Management Industry is poised to achieve a valuation of US$ 3649.90 Million by 2033, with a key focus on developing new drugs and therapies | FMI

During the forecast period of 2023 to 2033, the global idiopathic pulmonary fibrosis management industry size is anticipated to grow at a CAGR of 1.5% from a market value of US$ 3145 million in 2023 to US$ 3649.90 million. The rising prevalence of the condition in men around the world is responsible for the expansion of the idiopathic pulmonary fibrosis management market. From 2018 to 2022, the market for treating idiopathic pulmonary fibrosis grew at a CAGR of 1%.

Several diagnostic methods exist for identifying IPF, and guidelines for diagnosis have been established. Tests such as pulmonary function tests are used to evaluate restrictive lung disease, which is indicated by decreased lung volume (specifically, reduced forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity.

Request A Sample Copy of This Research Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16472

Furthermore, North America and Europe are two major regions contributing to the growth of the Idiopathic pulmonary fibrosis management market. This is owing to the high prevalence of the ailment in regions such as the Unites States of America and Germany. In addition, availability of various drugs along with innovative medication is shaping the landscape for the Idiopathic pulmonary fibrosis management market.

Key Takeaways from the Market Study:

  • Idiopathic pulmonary fibrosis management market is expected to grow at a value of 1.5% CAGR in the forecast period 2023 to 2033.
  • By distribution channel, retail pharmacies are expected to possess 40% market share for Idiopathic pulmonary fibrosis management market in 2023.
  • North America is expected to possess 45% market share for Idiopathic pulmonary fibrosis management market in 2023.
  • Europe is expected to hold 40% market share for Idiopathic pulmonary fibrosis management market in 2023.

“The presence of a wide range of drugs, as well as new and innovative medications, is influencing the market for managing Idiopathic pulmonary fibrosis.” states an FMI analyst

Customization Unleashed: Learn How to Stand Out in a Competitive Landscape! https://www.futuremarketinsights.com/customization-available/rep-gb-16472

Competitive Landscape:

Key players in the idiopathic pulmonary fibrosis management market are

  • Boehringer Ingelheim GMBH
  • Biogen
  • Novartis AG
  • Medicinova Inc
  • Bristol Myers Squibb Company
  • Galapagos NV
  • Hoffmann-La Roche AG
  • Neopharm Group
  • Galecto Biotech
  • Pfizer Inc
  • Johnson & Johnson Services, Inc most recent research includes the development of a drug called losmapimod, which is an oral p38 MAPK inhibitor. The drug is currently under clinical trials.
  • AstraZeneca most recent research includes the development of a drug called MEDI3039, which is a monoclonal antibody that targets the protein connective tissue growth factor (CTGF) and is in the phase 1b/2a clinical trial stage.

Act Now to Explore In-Depth Market Analysis: Get Exclusive Discount Now to Access! https://www.futuremarketinsights.com/checkout/16472

Key Segments Profiled in the Idiopathic Pulmonary Fibrosis Management Industry Survey:

Drug Class:

  • Pirfenidone
  • Nintedanib
  • Interferon Gammato1b
  • Others

Treatment:

  • Oxygen Therapy
  • Lung Transplant
  • Others

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain:

Idiopathic Thrombocytopenic Purpura Therapeutics Market Size: The global idiopathic thrombocytopenic purpura therapeutics market is expected to grow at a CAGR of 5.4% during the period 2022-2032. The market is valued at US$ 642 million as of 2022, and by 2032, the market is expected to be valued at US$ 1,086.28 million.

Cystic Fibrosis Therapeutics Market Share: The global Cystic Fibrosis Therapeutics Market size is expected to be valued at US$ 12.5 Billion in 2023. With the implementation of innovative treatment options for early detection, the overall demand for Cystic Fibrosis is projected to grow at a CAGR of 25.0% between 2023 and 2033, totalling around US$ 116.42 Billion by 2033.

Radiation-Induced Fibrosis Treatment Market Trends: According to Future Market Insights research, during the projected period, the global radiation induced fibrosis treatment market is expected to grow at a CAGR of 6.4%. The market value is projected to increase from US$ 73.8 Million in 2023 to US$ 137.1 Million by 2033.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Anti-Biofilm Wound Dressing Industry Poised for Remarkable Growth, Set to Reach US$ 1939.45 Million by 2033 | FMI

The global anti-biofilm wound dressing industry demand is on track to witness substantial growth, projected to surge from US$ 782.60 million in 2023 to an estimated US$ 1939.45 million by 2033, marking an impressive Compound Annual Growth Rate (CAGR) of 9.5%. This anticipated growth is fueled by an increasing prevalence of both acute and chronic wounds, which is driving the demand for specialized wound care solutions.

The anti-biofilm wound dressing market is a vital segment within the healthcare industry, dedicated to developing and providing innovative wound dressings tailored to combat biofilm formation in wounds. Biofilms, intricate communities of microorganisms like bacteria and fungi, pose significant challenges in chronic wounds, hindering the healing process, contributing to persistent infections, and elevating the risk of complications.

Request A Sample Copy of This Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16474

Designed with cutting-edge technology, anti-biofilm wound dressings aim to prevent, disrupt, or remove biofilms from wounds, thereby fostering faster and more effective wound healing. These dressings often incorporate antimicrobial agents and other advanced technologies to inhibit or eradicate biofilm formation, in addition to providing crucial functions such as moisture management, exudate absorption, and wound bed protection.

The market for anti-biofilm wound dressings has experienced robust growth in recent years, primarily due to the escalating prevalence of chronic wounds like diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The demand for these specialized dressings is driven by the urgent need for advanced wound care products capable of addressing the unique challenges posed by biofilms, ultimately improving healing outcomes.

A lead analyst at Future Market Insights emphasizes the pivotal role played by telehealth in the resounding recovery of the wound care market. Various healthcare providers have successfully implemented telehealth platforms to manage patients with chronic and acute wounds effectively, contributing to the overall positive trajectory of the industry.

As the global anti-biofilm wound dressing market continues its upward trajectory, manufacturers, healthcare providers, and investors are urged to seize the opportunities presented by this burgeoning sector. With innovation driving the industry, the future promises advancements that will redefine wound care and positively impact patient outcomes worldwide.

Key Takeaways from Market Study:

  • The market for anti-biofilm wound dressing is expected to record a CAGR of 9.5% over the forecast period.
  • According to estimates, the anti-biofilm wound dressing market in North America may remain strong throughout the length of the forecast period.
  • Acute wound segment dominated the market and is expected to record a CAGR of 9.3%.

Innovative Strategies Unveiled: Customization at the Core of Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16474

Competitive Landscape:

  • Several prominent companies dominate this market, including ConvaTec, Smith & Nephew PLC, Urgo Medical, Coloplast, and 3M.
  • Anti-biofilm wound dressing has developed significantly in the industry through partnerships, acquisitions, and research and development. These strategies have resulted in major developments.

Recent Developments:

  • Convatec Inc. acquired Triad Life Sciences Inc. in March 2022 for US$ 450 million. This acquisition was made with the aim of strengthening its portfolio of biomedical products for surgical wounds and chronic wounds.
  • The FDA cleared an antimicrobial matrix product made by Imbed Biosciences, Microlyte Matrix, in April 2021. The product can be used to treat surgical, traumatic, and chronic wounds.
  • For the treatment of diabetic foot ulcers, pressure ulcers, leg ulcers, and dehisced surgical wounds, ConvaTec Group Plc (ConvaTec) launched a new medication called “ConvaMax” in January 2020. As well as adhesion-free options, the product is also available in non-adhesive forms, allowing for total flexibility when it comes to integrating compression bands and other main dressings.
  • In January 2018, Imbed Biosciences introduced the market with Microlyte Ag after raising over US$ 1.6 million to research silver-based anti-biofilm wound dressings.
  • As a result of this acquisition, Smith & Nephew PLC expanded its product portfolio for advanced wound management, increasing its market share and customer base. In April 2019, the company acquired Osiris Therapeutics, Inc., a regenerative medicine company. As a result of this acquisition, the company will boost its growth by expanding its product portfolio for advanced wound management.

Our Analyst Is Available To Help You With Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16474

Anti-biofilm Wound Dressing Market Segmentation by Category:

By Mode of Mechanism:

  • Physical
  • Chemical
  • Biological

By Wound Type:

  • Chronic Wounds
  • Acute Wounds

By End User:

  • Hospitals and Clinics
  • Surgical Centers
  • Other End users

By Region:

  • North America
  • Latin America
  • Europe
  • The Middle East and Africa
  • East Asia

Unlock Exclusive Market Segments Insights: Buy Now! https://www.futuremarketinsights.com/checkout/16474

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Set to Surge, Projected to Reach US$ 288.5 Million by 2033, as per FMI

The global eosinophilic granulomatosis with polyangiitis treatment industry demand, valued at US$ 173.8 Million in 2023, is poised for substantial growth at a CAGR of 5.2%. A comprehensive market analysis forecasts an impressive escalation, driven by technological advances in healthcare, reaching an estimated US$ 288.5 Million by 2033.

Several factors contribute to this anticipated growth, including the increasing prevalence of Churg Strauss syndrome, allergic reactions, and asthma. The rising geriatric population, coupled with a surge in Churg Strauss syndrome cases among children, further fuels the market’s expansion during the assessment period.

Request A Sample Copy Of This Research Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16455

One of the driving forces behind this growth is the heightened awareness among patients about eosinophilic granulomatosis with polyangiitis and the availability of effective therapeutics. Developed economies are expected to witness a robust market boost due to these factors, while government support, coupled with the development of healthcare facilities and infrastructure, will contribute to the overall market development in the forecast period.

The development of modern therapeutics and a growing number of players with a robust drug pipeline are identified as key factors poised to significantly impact the global eosinophilic granulomatosis with polyangiitis treatment market in the coming years. Manufacturers are actively engaged in scaling up the production of treatment options for eosinophilic granulomatosis with polyangiitis, with ongoing research and innovation to introduce cutting-edge products.

Geographically, North America leads the eosinophilic granulomatosis with polyangiitis treatment market, benefiting from the presence of key market players, recent product launches, and a well-established healthcare infrastructure. Meanwhile, significant research and development investments in Europe position the region favorably for sustained market growth.

The industry’s optimistic trajectory is further bolstered by ongoing efforts to bring innovative products to market and meet the growing demand for eosinophilic granulomatosis with polyangiitis therapeutics. The collaboration between key stakeholders, government support, and advancements in healthcare technology collectively set the stage for a promising future in the global eosinophilic granulomatosis with polyangiitis treatment market.

As the market continues to evolve, stakeholders are encouraged to stay abreast of emerging trends and developments, ensuring they are well-positioned to capitalize on the immense opportunities presented by the growing demand for eosinophilic granulomatosis with polyangiitis treatment.

Key Takeaways from the Market Study:

  • As of 2023, the eosinophilic granulomatosis with polyangiitis treatment market was valued at US$ 173.8Million
  • From 2023 to 2033, the eosinophilic granulomatosis with polyangiitis treatment industry is poised to grow at 5.2% CAGR
  • By 2033, the eosinophilic granulomatosis with polyangiitis treatment market is slated to reach a valuation of US$ 288.5 Million
  • Based on the distribution channel, hospital pharmacy segment accounts for market share of 35.7% during the forecast period.
  • China is poised to yield a CAGR of 4.8% with respect eosinophilic granulomatosis with polyangiitis treatment in 2033.

Get In Touch With Our Analyst To Resolve Any Doubts You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16455

“Growing healthcare spending and growing the incidence of asthma across the world and rapid rise in the geriatric population are expected to radically transform the market in the coming years,” comments an analyst at FMI.

Competitive Landscape:

Some of the key players present in the global eosinophilic granulomatosis with polyangiitis treatment markets are

  • Genentech Inc
  • F. Hoffmann-La Roche AG
  • Cephalon Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Sanofi S.A.
  • Koninklijke DSM N.V
  • AstraZeneca
  • Novartis International AG
  • GlaxoSmithKline LLC
  • Baxter Healthcare Corporation

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industries.

  • In April 2021 – Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair®(omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
  • In December 2020– Amgen announced that the S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA).

Personalized Experiences Redefined: Our Customization Report Holds the Answers! https://www.futuremarketinsights.com/customization-available/rep-gb-16455

Key Segments Covered in Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Survey:

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Drug Class:

  • Steroids
  • Immunosuppressant
  • Biologics
  • Immune Globulins

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Drug stores
  • Retail Pharmacies
  • Online Pharmacies

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Inquire Before Buying This Research Report https://www.futuremarketinsights.com/checkout/16455

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Packaging Pets: Unwrapping the Growth Trajectory of the Europe Pet Food Packaging Market

The increasing preference for premium, nutrient-rich pet food, coupled with a surge in spending on pet-related products, is expected to be a significant catalyst for the heightened demand in pet food packaging across Europe. Furthermore, the market is propelled by the necessity for packaging solutions that effectively preserve food quality and extend shelf life.

As per the recent research report by FMI, a market research and competitive intelligence provider, sales of Europe Pet Food packaging Market are estimated to reach a value of US$ 5.06 billion by 2033, recording a CAGR of 4.4% over the forecast period.

The growth of the pet food packaging industry in Europe is influenced by the dual factors of a rising urban population and an uptick in pet adoption rates. This has generated a demand for accessible, high-quality pet food items, driving the versatile nature of pet food packaging.

Get an Exclusive Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16564

Drivers:

  1. E-commerce Growth: The growth of online pet food sales has led to the need for efficient and protective packaging solutions for shipping and delivery.
  2. Rising Pet Ownership: Increasing pet ownership rates across Europe are driving the demand for pet food, consequently boosting the pet food packaging market.
  3. Humanization of Pets: As pets are increasingly considered part of the family, there is a growing demand for high-quality and premium pet food products, which require specialized packaging.
  4. Sustainability Concerns: There is a growing awareness of the environmental impact of packaging materials, driving the demand for eco-friendly and recyclable pet food packaging.
  5. Regulatory Compliance: Stringent regulations regarding pet food packaging safety and labeling necessitate continuous innovation in packaging materials and technologies.

Market Opportunities

The surge in online shopping for pet food products has fueled a growing demand for convenient packaging solutions. This emergent trend is reshaping the pet food packaging landscape as consumers seek packaging that aligns with the convenience of online purchases.

The escalating demand for pet food packaging in developing countries provides a strategic opportunity for European manufacturers to broaden their market reach and explore new territories. As the pet ownership trend gains momentum in these regions, the need for innovative and efficient packaging solutions becomes increasingly pronounced.

Request Report Methodology:  https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16564

Latest Developments

In a strategic move, Amcor announced its acquisition of a state-of-the-art flexible packaging facility in the Czech Republic in August 2022. This acquisition positions Amcor strategically to cater to the burgeoning customer base and the escalating demand for flexible packaging in the region, leveraging the advantageous location of the newly acquired facility.

Amcor continued its trailblazing innovations with the introduction of HeatReadyTM AmLite HeatFlexTM Recycle-Ready in October 2020. Marking a significant milestone, this pioneering product represents the world’s first flexible retort pouch. Specifically designed for wet cat food, this award-winning container boasts high-barrier properties and exceptional heat resistance. Notably, the mono-PP pouch is not only cutting-edge in functionality but also aligns with sustainability goals, being easily recyclable within existing plastic recycling systems. This innovative solution reflects Amcor’s commitment to pushing the boundaries of packaging technology while addressing environmental considerations.

Competitive Landscape

Pet food has a strong competitive market in Europe. As more pets are being adopted, people in Europe are looking for luxury pet foods that are nutrient-dense and have useful qualities. The demand for pet food in the region is driven by all of these causes. While the demand for pet food has remained stable in the majority of EU nations, the pet food business in Eastern Europe is still in its infancy.

Some of the leading companies offering Europe Pet Food Packaging Market include: Berry Global Inc., Sonoco Products Company, Constantia Flexibles, Huhtamaki OYJ, Smurfit Kappa, Ardagh Group S.A, AptarGroup, Inc, Goglio S.p.A

Market Segmentation

By Material:

  • Paper & Paperboard
  • Plastic
  • Metals
  • Others

By Product Type:

  • Cans
  • Bags & Pouches
  • Folding Cartons
  • Tubes
  • Blister Pack
  • Plastic Bottles & Jars
  • Others

By End Use:

  • Dog Food
  • Cat Food
  • Fish Food
  • Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer, Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:  sales@futuremarketinsights.com
Website:  https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Chronic Refractory Cough Treatment Industry is projected to reach US$ 17.1 Billion by 2033, driven by a 6.39% CAGR | FMI

The global chronic refractory cough treatment industry size is poised to witness substantial growth, projected to reach a value of US$ 17.1 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 6.39%, according to recent market analysis. In 2023, the market is estimated to be worth US$ 9.2 billion. The surge in market value is attributed to the escalating prevalence of refractory chronic cough worldwide.

Chronic refractory cough (CRC) is characterized by a persistent cough that does not respond to standard treatments and persists for more than eight weeks. This condition significantly impacts the quality of life for affected individuals, necessitating specialized medical attention.

Discover Our Expert Analysis with Our Sample Report!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16436

The driving forces behind the expansion of the Chronic Refractory Cough Treatment market are manifold. Factors such as air pollution, smoking, respiratory tract infections, and underlying medical conditions like asthma and gastroesophageal reflux disease (GERD) contribute to the rising global prevalence of chronic refractory cough.

Pharmaceutical companies are poised to benefit from this market growth, enhancing their market share. The uptick in global healthcare spending and increased disease awareness are facilitating the expansion of the market. As a result, pharmaceutical and healthcare sectors are focusing on innovative and modern techniques to more effectively treat this persistent condition.

The pharmaceutical and healthcare sector’s commitment to addressing chronic refractory cough aligns with its dedication to improving patient outcomes and quality of life. Ongoing research and development activities are centered on developing advanced medications and treatments to alleviate the symptoms of chronic refractory cough, providing hope for affected individuals.

The upward trajectory of the Chronic Refractory Cough Treatment market underscores the urgency for collaborative efforts among healthcare professionals, researchers, and pharmaceutical companies to advance solutions and improve treatment options for those suffering from this challenging condition.

In conclusion, the global chronic refractory cough treatment market is set to witness substantial growth, presenting opportunities for innovation and collaboration within the pharmaceutical and healthcare sectors. As awareness and understanding of chronic refractory cough increase, there is a collective effort to enhance treatment modalities and improve the lives of individuals affected by this persistent condition.

The market offers various treatment options for chronic refractory cough, including:

  • Medications: Antitussive drugs such as opioids, neuromodulators, and non-opioids may be prescribed to suppress the cough reflex and provide relief.
  • Speech therapy: Techniques like cough suppression, cough control, and respiratory retraining may be employed to manage chronic refractory cough.
  • Inhalers: Bronchodilators and corticosteroid inhalers may be used to alleviate cough symptoms associated with underlying respiratory conditions.
  • Nerve stimulation: Certain therapies involve the electrical stimulation of nerves involved in cough reflexes to reduce cough frequency and severity.
  • Surgery: In severe cases of chronic refractory cough, surgical interventions like vagus nerve stimulation or tracheostomy may be considered as a last resort.

The Chronic Refractory Cough Treatment market is highly competitive, with pharmaceutical companies and healthcare providers actively involved in research and development to introduce innovative therapies and improve patient outcomes. The market’s growth is also supported by increased awareness about chronic refractory cough among healthcare professionals and patients, leading to early diagnosis and intervention.

Our Analyst Is Available To Help You With Any Inquiries You May Have!
https://www.futuremarketinsights.com/ask-question/rep-gb-16436

Top Companies Profiled:

  • Bayer AG
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Mylan N.V.
  • GSK Plc.
  • Hikma Pharmaceuticals Plc
  • AstraZeneca Plc.
  • Bausch Health
  • Novartis AG
  • Cipla Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Alitair Pharmaceuticals
  • NeRRe Therapeutics
  • Amneal Pharmaceuticals Inc.

Key Segments Profiled in the Chronic Refractory Cough Treatment Industry Survey:

By Drug Class:

  • Antibiotics
  • Decongestants
  • Corticosteroids
  • Antihistamines
  • Acid Blockers
  • Others

By Route of administration:

  • Oral
  • Nasal
  • Parenteral
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Empowering Businesses Worldwide: Our Customization Report Lights the Way!
https://www.futuremarketinsights.com/customization-available/rep-gb-16436

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Industry to Exceed US$ 7.29 Billion by 2033, Reports Indicate a CAGR of 4.2% | FMI

The global Diamond-Blackfan Anemia (DBAAASE) Syndrome therapeutics industry size is set to witness remarkable growth, with projections indicating a compound annual growth rate (CAGR) of 4.2% from 2023 to 2033. The industry size is expected to surpass an impressive US$ 4.8 billion in 2023 and is anticipated to reach a value of US$ 7.29 billion by 2033.

Diamond-Blackfan Anemia (DBA) is a rare genetic disorder characterized by hematologic problems, affecting 90% of individuals within their first year of birth. The surge in cases has driven substantial growth in the global market for DBAAASE syndrome therapeutics, with factors such as shifting lifestyles, increased government research and development funding, and rapid technological advancements expected to further propel market expansion over the forecast period.

Get Sample Copy of Latest Reports! https://www.futuremarketinsights.com/reports/sample/rep-gb-16433

North America currently dominates the DBAAASE syndrome therapeutics market, owing to the presence of key stakeholders, high disposable income, escalating healthcare expenses, and a well-established medical industry in the region. According to a report released by the Cleveland Clinic, the DBA Registry of North America reveals that 25% of individuals with DBA succumb to associated medical conditions before the age of 50.

“The growth of the Diamond-Blackfan Anemia (DBAAASE) Syndrome therapeutics market underscores the urgent need for innovative treatments and interventions to address this rare genetic disorder,” said Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.). “We are committed to advancing research and development efforts, contributing to the overall improvement of patient outcomes and the quality of life for those affected by DBA.”

As the market continues to evolve, industry players are expected to collaborate on pioneering solutions, leveraging advancements in medical technology and capitalizing on increased government support for research initiatives. The global community’s focus on improving healthcare outcomes for individuals with Diamond-Blackfan Anemia aligns with the industry’s commitment to addressing the unique challenges posed by this rare genetic disorder.

Key Takeaways from the Market Study:

  • Global DBAAASE syndrome therapeutics market to expand 1.5x from 2023 to 2033
  • By treatment, blood transfusions to experience a growth rate of 6.9%
  • Around 2 out of 5 DBAAASE syndrome therapeutics to happen across North America
  • Europe to emerge as an important contributor, expected to surge at a CAGR of 3.7%
  • Treatment through corticosteroids to gain equal traction as blood transfusions

“As medical science expands, treatments and therapies for a broad range of blood disorders is gaining major traction. This is boding well for the market on diamond blackfan anemia syndrome, with healthcare providers introducing a plethora of therapies and treatment approaches,” says an FMI analyst.

Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-16433

Key Market Players

Key players in the Diamond–Blackfan Anemia (DBA)/Aase Syndrome Therapeutics market are

  • Sumitomo Corporation
  • Johnson & Johnson Private Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • Merck & Co. Inc.
  • LEO Pharma A/S
  • Cipla Limited
  • GSK Plc.
  • AstraZeneca Plc.
  • Abbott Laboratories
  • Bayer AG

Recent Development:

In July 2021, AstraZeneca procured Alexion Pharmaceuticals, a global biotech company. With this acquisition, the company will be able to enter the market for rare disease medicines, ushering in a new chapter. Moreover, the acquisition strengthened AstraZeneca’s scientific presence in immunology and would allow the company to continue to pioneer the discovery and development of medicines for patients with rare diseases using Alexion’s new complement-biology system and robust pipeline.

In June 2022, Pfizer will collaborate with Sirana Pharma, a biotechnology company. The collaboration would help Pfizer recognize and validate a novel therapeutic concept for unique and severe bone diseases.

Revolutionizing Customer Engagement: Learn from Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16433

Key Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Industry Survey:

By Treatment:

  • Corticosteroids
  • Chelation Therapy
  • Blood Transfusions
  • Stem Cell Transplant
  • Others

By End User:

  • Hospitals
  • Clinics
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Sustainable Packaging Triumph: The Role of Corrugated Board in Eco-Friendly Solutions

The global corrugated board market is anticipated to reach US$ 143.86 billion in 2023, growing at a 6.8% CAGR between 2023 and 2033. The market is expected to reach US$ 277.75 billion by 2033.

In the projected timeframe, market growth is expected to be influenced by the prohibition of plastic packaging in emerging economies like India, the surge in industrialization, and the expansion of global trade. The widespread incorporation of corrugated boards in items such as liquid bottles, fruits and vegetables, ready-to-eat food, and confectionery products is foreseen to drive the expansion of the corrugated board market.

The market is predicted to be driven over the next years by an increase in online sales as well as a growth in consumer awareness of sustainable packaging. Government regulations regulating the safety of food packaging and the desire for better packaging materials are expected to cause the market to expand in the future years.

The e-commerce industry is experiencing robust growth due to various factors, including the surge in online shopping driven by the pandemic and the convenience of accessing a vast array of products through online retail platforms. As the demand for a diverse range of products online continues to rise, e-commerce companies are expanding their warehousing infrastructure to accommodate the increasing demand.

Corrugated boxes are now much more in demand as a result of this issue. The corrugated board market would increase significantly with the help of these points.

Get an Exclusive Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16560

Opportunities 

Smurfit Kappa is at the forefront of embracing digitalization within the corrugated board market, revolutionizing the landscape with a spectrum of innovative products. Renowned as a leading producer of corrugated packaging solutions, Smurfit Kappa has elevated the corrugated business by seamlessly integrating digitalization into its operations.

A recent milestone includes the introduction of a cutting-edge line of multifunctional paper specifically designed to harmonize with both flexographic and digital printers. This breakthrough in multifunctional paper technology facilitates a seamless synergy between the printer and the packaging material. This innovative approach expands the parameters for optimal digital printing, unlocking the full potential of this technology and pushing the boundaries of what can be achieved in the corrugated packaging industry. Smurfit Kappa’s commitment to digitalization is not just a technological upgrade but a strategic move toward enhancing efficiency and unleashing new possibilities in the realm of corrugated solutions.

Key Takeaways

  • The Japan market is expected to register a CAGR of 6.7% during the forecast period.
  • During the projected period, the corrugated board market in the United States accounted for approximately 19.1% of the global corrugated board industry.
  • During the forecast period, Sweden’s market accounted for around 6% of the global market.
  • Asia Pacific emerged as a prominent market, accounting for more than 40% of total revenue.

Recent Development

A new production line may be constructed at Mondi Group’s corrugated box production plant in Szczecin, Poland, in September 2021. As a result of the growth, this company’s packaging range may grow, and production processes may be streamlined.

Bobst, a corrugated board firm, may offered new portfolio of products and services in June 2022 to assist converters and brand owners with digitization and sustainability. Connectivity, digitization, automation, and sustainability have been promoted as the ‘four key pillars’ of the printing and packaging machinery. This assists this company in promoting its items.

Purchase this report to Uncover Segment-specific Information, Identify Key Trends, Drivers, and Challenges: https://www.futuremarketinsights.com/checkout/16560

Key Players

  • International Paper
  • Georgia-Pacific
  • WestRock Company
  • Packaging Corporation of America
  • Stora Enso
  • Oji Holdings Corporation
  • Smurfit Kappa
  • Port Townsend Paper Company
  • Mondi
  • DS Smith

Key Segments

By Flute Type:

  • Flute A
  • Flute B
  • Flute C
  • Flute E
  • Flute F

By Board Type:

  • Single Wall
  • Double Wall
  • Triple Wall

By End Use:

  • Food & Beverages
  • Pharmaceuticals
  • Cosmetics & Personal Care
  • Automotive
  • Transportation & Logistics

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani  

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube